The Medical Takeaways from Brian Johnson (Liver King)'s TRT Story

By
Published Updated Last reviewed
Hormone therapy clinical care image for The Medical Takeaways from Brian Johnson (Liver King)'s TRT Story

At a glance

  • Status: Confirmed. Johnson admitted on camera in December 2022 to using testosterone, trenbolone, growth hormone, and hCG after leaked emails revealed monthly spending exceeding $11,000 on performance-enhancing drugs.
  • Drug family: Anabolic-androgenic steroids and peptide hormones (not standard TRT).
  • Key clinical distinction: Johnson's admitted regimen was a multi-compound bodybuilding stack. Legitimate TRT uses testosterone alone at physiologic replacement doses.
  • Why it matters for patients: His case illustrates how supraphysiological dosing distorts public expectations of what testosterone therapy can and should do.

The Public Record

Brian Johnson built a social media following of millions by promoting what he called the "ancestral lifestyle," eating raw organ meats, performing unconventional workouts, and maintaining an extremely muscular, lean physique well into his 40s. He repeatedly attributed his body composition to diet, training, and supplementation with his own branded products.

In late November 2022, leaked emails between Johnson and a bodybuilding coach detailed a monthly pharmaceutical protocol reportedly costing over $11,000. The list included testosterone, trenbolone, growth hormone, hCG, and additional compounds. Within days, Johnson posted a video apology on YouTube confirming the use of anabolic steroids and hormones, stating he had "been on stuff" and that lying about it was "wrong."

The admission was significant not because a muscular influencer used performance-enhancing drugs, but because Johnson had specifically and repeatedly denied it. He had built a commercial brand on the premise that his results were achievable through lifestyle alone.

What He Actually Admitted To: A Pharmacological Breakdown

The leaked protocol and Johnson's own confirmation referenced four primary compounds. Each carries a distinct clinical profile that patients considering legitimate hormone therapy should understand.

Testosterone (Supraphysiological Doses)

Testosterone is the foundation of both TRT and anabolic steroid cycles, but the doses differ by an order of magnitude. Clinical TRT typically targets serum testosterone levels of 400 to 700 ng/dL, achieved with doses of 75 to 100 mg per week of testosterone cypionate or enanthate. Bodybuilding cycles commonly use 300 to 600 mg per week or more.

At supraphysiological levels, testosterone increases lean mass and reduces fat mass beyond what training alone can produce. A landmark 1996 study in The New England Journal of Medicine showed that 600 mg/week of testosterone enanthate with no exercise produced greater gains in fat-free mass than natural training alone. That result, while striking, came with dose-dependent increases in LDL cholesterol, hematocrit, and hepatic stress markers.

Trenbolone

Trenbolone is a veterinary anabolic steroid with no approved human indication. It binds the androgen receptor roughly five times more potently than testosterone. It is not prescribed in any clinical setting, and its use in humans is entirely extralegal.

The compound is associated with significant cardiovascular toxicity. Animal data show trenbolone accelerates atherosclerotic plaque formation and impairs cardiac contractility. Users frequently report insomnia, excessive sweating, and psychological effects including heightened aggression and anxiety. Because trenbolone does not aromatize to estrogen, it bypasses one of the body's feedback mechanisms, creating a hormonal environment that is difficult to manage without additional drugs.

Human Growth Hormone (hGH)

Growth hormone at supraphysiological doses promotes lipolysis and can increase lean body mass, contributing to the dense, full-muscle appearance common in enhanced bodybuilders. The Endocrine Society's clinical guidelines approve GH replacement only for documented adult GH deficiency, with starting doses of 0.1 to 0.3 mg/day.

At higher bodybuilding doses (2 to 5 IU daily or more), GH carries risks including insulin resistance, joint pain, carpal tunnel syndrome, and potential acceleration of occult malignancies. Long-term data on non-deficient adults using supraphysiological GH remain limited, which itself is a risk factor: patients are experimenting without a safety database.

Human Chorionic Gonadotropin (hCG)

hCG mimics luteinizing hormone, stimulating the testes to produce testosterone and maintain fertility during exogenous testosterone use. In clinical practice, hCG is sometimes co-prescribed with TRT at doses of 500 to 1 to 000 IU two to three times per week to preserve testicular volume and spermatogenesis.

In the context of a multi-compound bodybuilding stack, hCG serves a protective role: without it, the hypothalamic-pituitary-gonadal (HPG) axis shuts down, testes atrophy, and fertility can be impaired for months or years after discontinuation.

The Clinical Gap: Bodybuilding Stacks vs. Prescribed TRT

The HealthRX Medical Team considers this the central teaching point of Johnson's story. Patients frequently arrive at TRT consultations expecting physique changes that match what they see from enhanced influencers. The pharmacological reality is that standard TRT and a multi-compound stack are entirely different interventions.

| Parameter | Clinical TRT | Reported Bodybuilding Stack | |---|---|---| | Compounds | Testosterone only (occasionally + hCG) | Testosterone + trenbolone + GH + hCG + ancillaries | | Testosterone dose | 75 to 100 mg/week | 300 to 600+ mg/week | | Target serum level | 400 to 700 ng/dL | Often >1 to 500 ng/dL | | Monitoring | CBC, lipids, PSA every 6 to 12 months | Variable to none | | Expected body composition change | Modest: 3 to 6 lb lean mass gain over 12 months | Dramatic: 15 to 30+ lb lean mass gain per cycle | | Cardiovascular risk | Manageable with monitoring | Substantially elevated, dose-dependent |

Patients on legitimate TRT should expect gradual improvements in energy, libido, mood, and modest body composition changes over months. They should not expect to look like a competitive bodybuilder. When someone claims their physique comes from diet and lifestyle alone, the compounds listed above, not raw liver, explain the difference.

Discontinuation: What Happens When You Stop

Johnson's case also highlights a reality that influencers rarely discuss: what happens after the cycle ends. The HPG axis suppresses proportionally to the duration and intensity of exogenous androgen use.

After prolonged supraphysiological testosterone and trenbolone use, recovery of endogenous testosterone production can take 3 to 12 months or longer. Some men never fully recover baseline production and transition to lifelong TRT. During the recovery window, patients commonly experience fatigue, depression, loss of libido, and rapid loss of the muscle mass gained during the cycle.

For patients on physician-supervised TRT at standard doses, discontinuation is generally simpler, though the same axis suppression applies. The HealthRX Medical Team advises any patient starting TRT to understand that it is typically a long-term or lifelong commitment, not a short course.

The HealthRX Medical Team Take

Brian Johnson's story is clinically useful for one reason: it illustrates the distance between pharmaceutical muscle and what the human body produces on its own. His physique was built on at least four compounds running simultaneously at doses that far exceed any clinical protocol. Patients starting TRT deserve to know that their results will look nothing like his, and that is a feature of safe medicine, not a limitation.

The denial period matters too. Johnson spent years telling an audience of millions that his body was the product of eating ancestral foods. This created a false benchmark. When patients come to a TRT consultation frustrated that 100 mg/week of testosterone hasn't transformed their physique, the gap between expectation and reality often traces back to influencer content like his.

Three clinical principles from this case apply broadly:

Dose determines outcome and risk. The dose-response relationship for testosterone's anabolic effects is well established. More drug produces more muscle, but also more erythrocytosis, more dyslipidemia, and more hepatic and cardiovascular strain. There is no free lunch at 500 mg/week.

Stacking compounds multiplies unknowns. Combining testosterone with trenbolone and GH creates drug-drug interactions that have never been studied in controlled trials. Patients assume that widespread use implies safety. It does not.

Monitoring is non-negotiable. The American Urological Association recommends hematocrit, lipid panels, and PSA screening at regular intervals for any patient on testosterone. Johnson's leaked protocol included no mention of structured medical oversight. For patients on any hormone therapy, the bloodwork is as important as the prescription.

Frequently asked questions

›
›
›
›
›

References

  • Bhasin S, et al. "Testosterone dose-response relationships in healthy young men." Am J Physiol Endocrinol Metab. 2001. https://pubmed.ncbi.nlm.nih.gov/11701431/
  • Bhasin S, et al. "The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men." N Engl J Med. 1996. https://www.nejm.org/doi/full/10.1056/NEJM199607043350101
  • Mulhall JP, et al. "Evaluation and Management of Testosterone Deficiency: AUA Guideline." J Urol. 2018. https://pubmed.ncbi.nlm.nih.gov/29653984/
  • Budoff MJ, et al. "Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone." JAMA. 2017. https://jamanetwork.com/journals/jama/fullarticle/2767651
  • Molitch ME, et al. "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2011. https://academic.oup.com/jcem/article/96/6/1587/2833823
  • Liu PY, et al. "Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception." Lancet. 2006. https://pubmed.ncbi.nlm.nih.gov/33180028/
  • Dob AS, et al. "Growth hormone and aging." Endocrinol Metab Clin North Am. 2003. https://pubmed.ncbi.nlm.nih.gov/12023994/
  • Hsiao K, et al. "Impact of testosterone and hCG on testicular function and spermatogenesis." Curr Urol Rep. 2019. https://pubmed.ncbi.nlm.nih.gov/30653648/
  • Dos Santos MR, et al. "Cardiovascular effects of anabolic-androgenic steroids." Heart. 2021. https://pubmed.ncbi.nlm.nih.gov/25461682/